AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Longeveron LLC (NASDAQ:LGVN)
1.32 USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.32 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 40.000/1.030 |
| EBITDA (in USD) | -20.06M |
| PE Ratio | -- |
| Volume | 55597 |
| Diluted Eps TTM | -9.34 |
| Total Assets (in USD) | 12.178M |
|---|---|
| Total Liabilities (in USD) | 5.337M |
| Revenue TTM (in USD) | 0.709M |
| Cash (in USD) | 4.949M |
| Market Cap (in USD) | 6.791 M |
| Revenue Per Share TTM | 0.326 |
| Gross Profit TTM (in USD) | 0.497M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Life Science and Technology Park, Miami, FL, United States, 33136
305 909 0840
Employees: 23
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 1963 |
| 2. | Mr. James Clavijo CPA | CFO & Treasurer | 1966 |
| 3. | Mr. Paul T. Lehr J.D. | International Exec. Director, Gen. Counsel & Sec. | 1968 |
| 4. | Dr. Kwan-Hong Min M.D., Ph.D. | Chief Medical Officer & Interim CEO | 1967 |
| 5. | Dr. Dan Gincel Ph.D. | Sr. VP of Strategic Collaborations & Scientific Affairs | 1971 |
| 6. | Mr. Mohamed Wa'el Ahmed Hashad | CEO & Director | 1962 |
| 7. | Ms. Lisa A. Locklear M.B.A. | Executive VP & CFO | 1962 |
| 8. | Mr. Paul T. Lehr J.D. | International Executive Director, General Counsel & Secretary | 1968 |
| 9. | Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations & Scientific Affairs | 1971 |
| 10. | Dr. Nataliya Agafanova M.D. | Chief Medical Officer | 1970 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.560 0.691% | 81.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.410 0.506% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.290 0.280% | 455.39 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.820 0.540% | 518.25 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -18.835M | -17.045M | -3.721M | -2.96M | -6.337M |
| Minority Interest | - | - | - | - | - |
| Net Income | -19.627M | -17.164M | -3.791M | -2.996M | -6.337M |
| Selling General Administrative | 8.119M | 10.734M | 2.731M | 2.775M | 3.117M |
| Gross Profit | 0.497M | 0.59M | 1.826M | 1.754M | 0.681M |
| Reconciled Depreciation | 0.893M | 0.914M | 0.785M | 0.769M | 0.746M |
| Ebit | -18.043M | -17.456M | -3.778M | -2.998M | -6.337M |
| Ebitda | -17.437M | -16.427M | -2.929M | -2.191M | -5.591M |
| Depreciation And Amortization | 0.606M | 1.029M | 0.849M | 0.807M | 0.746M |
| Operating Income | -18.043M | -17.456M | -3.778M | -2.998M | -6.361M |
| Other Operating Expenses | 19.265M | 18.762M | 9.408M | 8.638M | 8.495M |
| Interest Expense | -0.287M | 0.004M | 0.007M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | 0M | 0.003M | 0.024M |
| Net Interest Income | 0M | -0.004M | -0.006M | 0.003M | 0.024M |
| Income Tax Expense | 0.792M | 0.119M | 0.07M | 0.036M | 0.024M |
| Total Revenue | 1.222M | 1.306M | 5.63M | 5.639M | 2.135M |
| Total Operating Expenses | 18.54M | 18.046M | 5.605M | 4.752M | 7.041M |
| Cost Of Revenue | 0.725M | 0.716M | 3.803M | 3.885M | 1.454M |
| Total Other Income Expense Net | -0.792M | 0.411M | 0.057M | 0.038M | 0.024M |
| Net Income From Continuing Ops | -18.835M | -17.045M | -3.721M | -2.96M | -6.337M |
| Net Income Applicable To Common Shares | -18.835M | -17.045M | -3.721M | -2.96M | -6.337M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 12.178M | 27.413M | 42.766M | 9.24M | 10.584M |
| Intangible Assets | 2.287M | 2.409M | 2.334M | 1.547M | 1.48M |
| Other Current Assets | 0.376M | 0.404M | 0.282M | 0.613M | 0.054M |
| Total Liab | 5.337M | 6.91M | 5.313M | 7.283M | 6.139M |
| Total Stockholder Equity | 6.841M | 20.503M | 37.453M | 1.957M | 4.445M |
| Other Current Liab | 2.152M | 2.048M | 1.327M | 1.542M | 0.305M |
| Common Stock | 0.025M | 0.021M | 0.021M | 2.057M | 4.595M |
| Capital Stock | 0.025M | 0.021M | 0.021M | - | - |
| Retained Earnings | -84.984M | -62.773M | -43.938M | - | - |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.244M | 2.327M | 0.002M | 0.251M |
| Cash | 4.949M | 10.503M | 25.658M | 0.816M | 1.866M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 3.889M | 4.869M | 2.708M | 3.83M | 2.487M |
| Current Deferred Revenue | 0.506M | 0.506M | 0.199M | 0.01M | 0.542M |
| Net Debt | -2.908M | -7.898M | -22.516M | 3.325M | 2.272M |
| Short Term Debt | 0.593M | 0.564M | 0.537M | 0.688M | 0.486M |
| Short Long Term Debt | - | - | - | 0.177M | - |
| Short Long Term Debt Total | 2.041M | 2.605M | 3.142M | 4.141M | 4.138M |
| Other Stockholder Equity | 91.8M | 83.612M | 81.37M | 1.957M | 6.546M |
| Property Plant Equipment | - | 2.949M | 3.062M | 5.666M | 6.482M |
| Total Current Assets | 5.848M | 19.658M | 35.38M | 1.849M | 2.371M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0.412M | 9.155M | 9.385M | - | - |
| Net Receivables | 0.111M | 0.218M | 0.055M | 0.421M | 0.451M |
| Long Term Debt | - | 2.041M | 2.605M | 0.312M | - |
| Inventory | - | -0.622M | 0.282M | - | - |
| Accounts Payable | 0.638M | 1.751M | 0.645M | 1.59M | 1.155M |
| Accumulated Other Comprehensive Income | -0.1M | -0.357M | - | - | -2.101M |
| Non Currrent Assets Other | 0.093M | 2.397M | 0.177M | 0.177M | 0.251M |
| Non Current Assets Total | 6.33M | 7.755M | 7.386M | 7.391M | 8.213M |
| Capital Lease Obligations | 2.041M | 2.605M | 3.142M | 3.652M | 4.138M |
| Long Term Debt Total | - | 2.041M | 2.605M | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.677M | -9.471M | -0.262M | -0.125M | -0.212M |
| Total Cashflows From Investing Activities | -0.677M | -10.696M | -0.262M | -0.125M | -0.212M |
| Total Cash From Financing Activities | -0.509M | 45.174M | 1.575M | 0.35M | 1.355M |
| Net Income | -18.835M | -17.045M | -3.721M | -2.96M | -6.337M |
| Change In Cash | -15.155M | 24.842M | -1.05M | -2.166M | -4.035M |
| Begin Period Cash Flow | 25.658M | 0.816M | 1.866M | 4.032M | 8.067M |
| End Period Cash Flow | 10.503M | 25.658M | 0.816M | 1.866M | 4.032M |
| Total Cash From Operating Activities | -13.969M | -9.636M | -2.364M | -2.391M | -5.178M |
| Depreciation | 0.893M | 0.914M | 0.785M | 0.769M | 0.746M |
| Other Cashflows From Investing Activities | -0.108M | -0.895M | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | -0.031M | - | - |
| Sale Purchase Of Stock | 0.002M | 45.813M | - | - | - |
| Other Cashflows From Financing Activities | -0.509M | 0.172M | 0.5M | 0.35M | 1.355M |
| Capital Expenditures | 0.856M | 1.31M | 0.262M | 0.125M | 0.212M |
| Change In Working Capital | 0.238M | -1.09M | 0.489M | -0.337M | -0.011M |
| Other Non Cash Items | 1.398M | -0.155M | 0.044M | 2.081M | - |
| Free Cash Flow | -14.825M | -10.946M | -2.625M | -2.516M | -5.39M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 17623 |
| 2. | BlackRock Extended Mkt Composite | 1 year ago | 17329 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 6509 |
| 4. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1 year ago | 4889 |
| 5. | Fidelity Extended Market Index | 1 year ago | 4309 |
| 6. | Fidelity Total Market Index | 1 year ago | 3344 |
| 7. | BlackRock Extended Equity Market K | 1 year ago | 1512 |
| 8. | SSgA U.S. Extended Market Index Class I | 1 year ago | 1200 |
| 9. | iShares Micro-Cap ETF | 1 year ago | 1010 |
| 10. | Fidelity Series Total Market Index | 1 year ago | 640 |
| 11. | NT Ext Equity Mkt Idx Fd - NL | 1 year ago | 609 |
| 12. | Fidelity Nasdaq Composite Index | 1 year ago | 500 |
| 13. | NT US Market Cap Idx Fd - L | 1 year ago | 465 |
| 14. | NT Ext Equity Mkt Idx Fd - L | 1 year ago | 400 |
| 15. | Northern Trust Extended Eq Market Idx | 1 year ago | 400 |
| 16. | SSgA U.S. Total Market Index Strategy | 1 year ago | 346 |
| 17. | Spartan Total Market Index Pool E | 1 year ago | 200 |
| 18. | Extended Equity Market Fund M | 1 year ago | 186 |
| 19. | State St US Extended Mkt Indx NL Cl C | 1 year ago | 120 |
| 20. | 1290 VT Micro Cap K | 1 year ago | 83 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 111700 |
| 2. | Creative Planning Inc | 1 year ago | 109322 |
| 3. | Geode Capital Management, LLC | 1 year ago | 90238 |
| 4. | Northern Trust Corp | 1 year ago | 49753 |
| 5. | Vanguard Group Inc | 1 year ago | 24132 |
| 6. | State Street Corporation | 1 year ago | 14800 |
| 7. | Tower Research Capital LLC | 1 year ago | 6812 |
| 8. | Wells Fargo & Co | 1 year ago | 4694 |
| 9. | Bank of America Corp | 1 year ago | 3905 |
| 10. | PNC Financial Services Group Inc | 1 year ago | 2970 |
| 11. | JPMorgan Chase & Co | 1 year ago | 2507 |
| 12. | UBS Group AG | 1 year ago | 1751 |
| 13. | Morgan Stanley - Brokerage Accounts | 1 year ago | 700 |
| 14. | Royal Bank of Canada | 1 year ago | 132 |
| 15. | Householder Group Estate & Retirement Specialist, LLC | 1 year ago | 100 |
| 16. | LGT Financial Advisors LLC | 1 year ago | 35 |
| 17. | TOWNSQUARE CAPITAL LLC | 1 year ago | 0 |
| 18. | One Wealth Management Investment & Advisory Services LLC | 1 year ago | 0 |
| 19. | Millennium Management LLC | 1 year ago | 0 |
| 20. | Lloyd Advisory Services, LLC | 1 year ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...